EligibleTrials

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

Recruiting · NCT03051464 · Interventional (participants receive a specific treatment) · Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital

View the official record on ClinicalTrials.gov →
Colorectal cancer

Interventions studied

Chemoradiation + EBRT BoostChemoradiation + HDRBT BoostComplete responders and Non-complete responders

What this trial is about

A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).

Who can take part

Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2, Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

4 locations listed across 1 US state.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.